Windtree Therapeutics (WINT) announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company’s Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics Inc (WINT) Q3 Earnings Cheat Sheet
- Windtree Therapeutics issued Hong Kong patent for istaroxime
- Windtree Therapeutics initiates SEISMiC C study of istaroxime
- Windtree Therapeutics completes national phase filings for istaroxime
- Windtree Therapeutics announces issuance of istaroxime patent for Japan